Bioheal Therapeutics

Executive Summary

Bioheal Therapeutics is a private, pre-revenue MedTech company headquartered in San Diego, developing advanced wound care solutions. Its lead product, Protevion™ Hydrogel, is a flowable amnion-derived hydrogel dressing designed to create an optimal healing environment for chronic wounds, burns, and post-surgical sites. The company's mission is to deliver affordable, easy-to-use advanced care that improves patient outcomes and reduces healthcare costs. Founded in 2018, the company has not yet disclosed funding or valuation, but its focus on regenerative medicine and cell therapy positions it in a growing market addressing the unmet need for effective chronic wound management, particularly for diabetes-related ulcers and pressure sores. Although Bioheal remains in the pre-revenue stage, the market potential is significant, with chronic wound care representing a multi-billion-dollar opportunity globally. The company's hydrogel leverages biological properties of amniotic membrane to promote healing, differentiating it from synthetic dressings. Key near-term milestones include regulatory clearance and early clinical validation. However, the absence of publicly available clinical data or funding history adds uncertainty. Bioheal's success hinges on achieving FDA clearance, securing partnerships for manufacturing and distribution, and demonstrating clinical efficacy. Given the early stage and lack of visible progress, the conviction score is moderate, reflecting promise tempered by execution risk.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Submission for Protevion Hydrogel60% success
• Q4 2026Clinical Trial Initiation for Chronic Wound Indication50% success
• Q2 2027Strategic Partnership or Distribution Agreement40% success